MYD88 MUTATIONS PREDICT UNFAVORABLE PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH MUTATED IGHV GENE

Qin, Shu-Chao,Xia, Yi,Miao, Yi,Zhu, Hua-Yuan,Wu, Jia-Zhu,Fan, Lei,Li, Jian-Yong,Xu, Wei,Qiao, Chun
DOI: https://doi.org/10.1002/hon.2439_144
IF: 9.812
2017-01-01
Blood Cancer Journal
Abstract:Introduction: Myeloid differentiation primary response gene 88 (MYD88) L265P mutations have been identified as a diagnostic biomarker in Waldenstrom's Macroglobulinemia (WM). However, little is known about the incidence and prognostic value of MYD88 mutations in Chinese chronic lymphocytic leukemia (CLL) patients. Methods: Using Sanger sequencing along with allele-specific polymerase chain reaction (AS-PCR), we studied the incidence, clinical associations and prognostic impact of MYD88 mutations in 284 Chinese CLL patients. Results: MYD88 mutations were detected in 25/284 (8.8%) previously untreated CLL patients in our center, including all mutations in exon 3-5. The hotspot L265P substitution was detected in 18/284 (6.3%) cases by AS-PCR. CLL patients carrying MYD88 mutations had a lower CD38 positive rate (p = 0.011) and CD200 MFI (p < 0.001) than those with wild-type MYD88 did. In addition, MYD88 mutations were more common in patients with mutated immunoglobulin heavy chain variable region (IGHV, 22/25 vs.143/254, p = 0.001). No correlation was observed between MYD88 mutations with other clinical characteristics including age, sex, Binet stage, CD23 and molecular abnormalities. Multivariate analysis confirmed MYD88 mutations to be an independent prognostic factor for shorter time-to-treatment in the IGHV-mutated subgroup. Keywords: chronic lymphocytic leukemia (CLL); MYD88; prognostic indices.
What problem does this paper attempt to address?